vs
Side-by-side financial comparison of GRI Bio, Inc. (GRI) and IMPACT BIOMEDICAL INC. (IBO). Click either name above to swap in a different company.
IMPACT BIOMEDICAL INC. is the larger business by last-quarter revenue ($18.0K vs $16.0K, roughly 1.1× GRI Bio, Inc.). IMPACT BIOMEDICAL INC. runs the higher net margin — -8166.7% vs -13437.5%, a 5270.8% gap on every dollar of revenue.
GRI Bio, Inc. is a clinical-stage biopharmaceutical firm developing innovative targeted therapies for autoimmune, inflammatory, and fibrotic diseases. Its product candidates address unmet medical needs, serving global healthcare markets to deliver improved outcomes for patients with underserved disease indications.
IMPACT BIOMEDICAL INC.IBOEarnings & Financial Report
The National Institute of Biomedical Imaging and Bioengineering (NIBIB), founded at the National Institutes of Health (NIH) in 2000, is located in Bethesda, Maryland. It is one of 27 institutes and centers that are part of NIH, an agency of the U.S. Department of Health and Human Services (HHS).
GRI vs IBO — Head-to-Head
Income Statement — Q1 FY2023 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.0K | $18.0K |
| Net Profit | $-2.1M | $-1.5M |
| Gross Margin | — | 94.4% |
| Operating Margin | -6175.0% | -5266.7% |
| Net Margin | -13437.5% | -8166.7% |
| Revenue YoY | — | — |
| Net Profit YoY | -611.9% | -134.6% |
| EPS (diluted) | $-15.04 | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $18.0K | ||
| Q2 25 | — | $7.0K | ||
| Q1 23 | $16.0K | — | ||
| Q3 22 | $2.0K | — | ||
| Q2 22 | $-1.0K | — | ||
| Q1 22 | $0 | — |
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $-14.3M | ||
| Q1 23 | $-2.1M | — | ||
| Q3 22 | $-351.0K | — | ||
| Q2 22 | $-295.0K | — | ||
| Q1 22 | $-302.0K | — |
| Q3 25 | — | 94.4% | ||
| Q2 25 | — | -57.1% | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | — | -5266.7% | ||
| Q2 25 | — | -16471.4% | ||
| Q1 23 | -6175.0% | — | ||
| Q3 22 | -9300.0% | — | ||
| Q2 22 | 18900.0% | — | ||
| Q1 22 | — | — |
| Q3 25 | — | -8166.7% | ||
| Q2 25 | — | -204942.9% | ||
| Q1 23 | -13437.5% | — | ||
| Q3 22 | -17550.0% | — | ||
| Q2 22 | 29500.0% | — | ||
| Q1 22 | — | — |
| Q3 25 | — | $-0.12 | ||
| Q2 25 | — | $-1.18 | ||
| Q1 23 | $-15.04 | — | ||
| Q3 22 | $-0.39 | — | ||
| Q2 22 | $-0.35 | — | ||
| Q1 22 | $-11.62 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7M | $12.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-3.2M | $-11.8M |
| Total Assets | $2.1M | $18.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $12.0K | ||
| Q2 25 | — | $624.0K | ||
| Q1 23 | $1.7M | — | ||
| Q3 22 | $4.7M | — | ||
| Q2 22 | $5.2M | — | ||
| Q1 22 | $2.5M | — |
| Q3 25 | — | $-11.8M | ||
| Q2 25 | — | $-10.3M | ||
| Q1 23 | $-3.2M | — | ||
| Q3 22 | $-5.7M | — | ||
| Q2 22 | $-5.4M | — | ||
| Q1 22 | $-5.2M | — |
| Q3 25 | — | $18.2M | ||
| Q2 25 | — | $19.1M | ||
| Q1 23 | $2.1M | — | ||
| Q3 22 | $5.6M | — | ||
| Q2 22 | $8.0M | — | ||
| Q1 22 | $5.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-579.0K | $-613.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-613.0K | ||
| Q2 25 | — | $-694.0K | ||
| Q1 23 | $-579.0K | — | ||
| Q3 22 | $-125.0K | — | ||
| Q2 22 | $2.2M | — | ||
| Q1 22 | $-2.3M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | 0.0% | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
